IPO Year: 2024
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2025 | $38.00 | Strong Buy | Raymond James |
| 12/15/2025 | $34.00 | Buy | Truist |
| 11/14/2025 | Equal Weight → Overweight | Wells Fargo | |
| 6/23/2025 | $26.00 | Buy | H.C. Wainwright |
| 2/18/2025 | $14.00 | Overweight → Equal Weight | Wells Fargo |
| 11/19/2024 | $38.00 | Overweight | Analyst |
| 11/19/2024 | Buy | TD Cowen | |
| 11/19/2024 | $43.00 | Overweight | Wells Fargo |
| 11/19/2024 | $50.00 | Overweight | Cantor Fitzgerald |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Raymond James initiated coverage of Septerna with a rating of Strong Buy and set a new price target of $38.00
Truist initiated coverage of Septerna with a rating of Buy and set a new price target of $34.00
Wells Fargo upgraded Septerna from Equal Weight to Overweight
H.C. Wainwright initiated coverage of Septerna with a rating of Buy and set a new price target of $26.00
Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00
Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00
TD Cowen initiated coverage of Septerna with a rating of Buy
Wells Fargo initiated coverage of Septerna with a rating of Overweight and set a new price target of $43.00
Cantor Fitzgerald initiated coverage of Septerna with a rating of Overweight and set a new price target of $50.00
10-Q - Septerna, Inc. (0001984086) (Filer)
8-K - Septerna, Inc. (0001984086) (Filer)
8-K - Septerna, Inc. (0001984086) (Filer)
8-K - Septerna, Inc. (0001984086) (Filer)
8-K - Septerna, Inc. (0001984086) (Filer)
10-Q - Septerna, Inc. (0001984086) (Filer)
8-K - Septerna, Inc. (0001984086) (Filer)
8-K - Septerna, Inc. (0001984086) (Filer)
8-K - Septerna, Inc. (0001984086) (Filer)
8-K - Septerna, Inc. (0001984086) (Filer)
Fastest customizable press release news feed in the world
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:45 p.m. PT in San Francisco. A live webcast of the presentation will be available in the investors section of the company's website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation. About SepternaSepterna, Inc. is a clinical-stage biotechn
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 a.m. ET in Coral Gables, Florida. A live webcast of the presentation will be available in the investors section of the company's website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation. About SepternaSepterna, Inc. is a clinical-stage biotechnology company with a world-class team of
SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust Financial Position of $561.6 Million Expected to Support Operations at Least into 2029 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates and upcoming milestones and reported financial results for the quarter ended September 30, 2025. "In the third quarter, we made meaningful progress across our portfolio, highlighted by the selection of
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation ConferenceFireside chat on Monday, November 10, 2025, at 4:00 p.m. ET TD Cowen Immunology & Inflammation SummitFireside chat on Wednesday, November 12, 2025, at 4:00 p.m. ET Live webcasts of the presentations will be available in the investors section of the company's website at www.septerna.com. Replays will be archived for at least
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Keith Gottesdiener, M.D., to its board of directors. A seasoned biotechnology executive with over 30 years of experience advancing medicines from discovery through commercialization, Dr. Gottesdiener will serve as chairperson of a newly constituted R&D Committee of the Board. "Dr. Gottesdiener's exceptional track record of successfully advancing novel therapeutics from discovery through development to approval, combined with his deep expertise in reg
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in September: Cantor Global Healthcare Conference 2025 Presentation on Wednesday, September 3, 2025, at 11:30 a.m. ET 2025 Wells Fargo Healthcare ConferenceFireside chat on Friday, September 5, 2025, at 8:45 a.m. ET Live webcasts of the presentations will be available in the investors section of the company's website at www.septerna.com. Replays will be archived for at least 30 days f
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule Mas-related G protein-coupled receptor X2 (MRGPRX2) negative allosteric modulator (NAM) being developed for the treatment of chronic spontaneous urticaria (CSU) and other mast cell-driven diseases. The Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodyna
Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates and upcoming milestones and reported financial results for the second quarter ended June 30, 2025. "We are executing effectively across our portfolio, with each program nearing important milestones," said Je
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 3:45 p.m. ET in New York. A live webcast of the presentation will be available here and in the investors section of the company's website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation. About SepternaSepterna, Inc. is a biotechnology company pioneering a new era of
Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later in 2025 Expect to Initiate Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, in Third Quarter of 2025 Ended First Quarter 2025 with $398.2 Million in Cash, Cash Equivalents and Marketable Securities; Novo Nordisk Collaboration to Significantly Extend Prior Runway Guidance of Early 2028 SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pi
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
3 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
This live feed shows all institutional transactions in real time.
SC 13D - Septerna, Inc. (0001984086) (Subject)
SC 13G - Septerna, Inc. (0001984086) (Subject)
SC 13G - Septerna, Inc. (0001984086) (Subject)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
Live Leadership Updates
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Keith Gottesdiener, M.D., to its board of directors. A seasoned biotechnology executive with over 30 years of experience advancing medicines from discovery through commercialization, Dr. Gottesdiener will serve as chairperson of a newly constituted R&D Committee of the Board. "Dr. Gottesdiener's exceptional track record of successfully advancing novel therapeutics from discovery through development to approval, combined with his deep expertise in reg
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. "We are excited to welcome Gil to the team," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "His extensive expertise leading public company finance and capital strategy will be ins